Abstract is: Kenneth Offit (born February 19, 1955) is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College, and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control. Offit has been widely recognized for his discoveries with respect to the genetic bases of breast, colon, and lymphoid cancers. In 2016, he was elected as a Member of the National Academy of Medicine. In 2018, he was named a Fellow of the American Society of Clinical Oncology. In 2021, he was named a fellow of the American Association for the Advancement of Science.
| human | Q5 |
| P2671 | Google Knowledge Graph ID | /g/11b81xt8v8 |
| P269 | IdRef ID | 178543896 |
| P213 | ISNI | 0000000117528598 |
| P244 | Library of Congress authority ID | n97801730 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 227897404 |
| P496 | ORCID iD | 0000-0002-7454-329X |
| P7293 | PLWABN ID | 9810609999205606 |
| P3368 | Prabook ID | 2131402 |
| P214 | VIAF ID | 315232727 |
| P10832 | WorldCat Entities ID | E39PBJjRVXTFPwdJ9p9FrbymVC |
| P166 | award received | Fellow of the American Association for the Advancement of Science | Q5442484 |
| P27 | country of citizenship | United States of America | Q30 |
| P69 | educated at | Princeton University | Q21578 |
| Harvard Medical School | Q49121 | ||
| P108 | employer | Memorial Sloan Kettering Cancer Center | Q1808012 |
| P734 | family name | Offit | Q41957549 |
| Offit | Q41957549 | ||
| Offit | Q41957549 | ||
| P735 | given name | Kenneth | Q2492643 |
| Kenneth | Q2492643 | ||
| P106 | occupation | geneticist | Q3126128 |
| oncologist | Q16062369 | ||
| P21 | sex or gender | male | Q6581097 |
| Q93147892 | 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood |
| Q44115883 | 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance |
| Q57907630 | 453 THE ASSOCIATION OF GENITOURINARY CANCERS WITH BRCA CARRIER STATUS IN A CLINICALLY TESTED COHORT FROM A SINGLE INSTITUTION |
| Q72233364 | 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma |
| Q35890189 | A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis |
| Q40495288 | A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q90909978 | A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen) |
| Q24803679 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment |
| Q52679854 | A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. |
| Q34881099 | A genome-wide association study of marginal zone lymphoma shows association to the HLA region |
| Q27851467 | A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms |
| Q34433744 | A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q37164443 | A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing |
| Q97519331 | A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers |
| Q34979383 | A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome |
| Q34369388 | A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia |
| Q74459364 | A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers |
| Q54788578 | A636P is associated with early-onset colon cancer in Ashkenazi Jews. |
| Q35934041 | A636P testing in Ashkenazi Jews |
| Q36601020 | ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes |
| Q50789980 | ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. |
| Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
| Q56928428 | Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families |
| Q37356519 | Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier |
| Q56928450 | Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes |
| Q57907595 | Abstract 1291: High and moderate penetrance germline mutations in a number of genes are responsible for a small proportion of familial breast cancer risk in BRCAx families |
| Q57907601 | Abstract 2378: Harmonization of next generation sequencing data within consortia for gene discovery in familial breast cancer |
| Q57907603 | Abstract 3282: Determination of cancer susceptibility in probands with breast and ovarian cancer |
| Q59059958 | Abstract 5071: A genome-wide association study suggests evidence of variants at 6p21.32 associated with marginal zone lymphoma |
| Q38437593 | Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. |
| Q104485780 | Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study |
| Q57266698 | Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q37238851 | Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. |
| Q37672016 | American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility |
| Q36286694 | An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q30840823 | Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping |
| Q24170413 | Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types |
| Q78428850 | Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer |
| Q45159522 | Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q34806183 | Assessment of SLX4 Mutations in Hereditary Breast Cancers |
| Q54996542 | Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families |
| Q56928424 | Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes |
| Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
| Q37588396 | Association of a HOXB13 variant with breast cancer |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q91855756 | Author Correction: Tumour lineage shapes BRCA-mediated phenotypes |
| Q41099432 | BCL-6 in diffuse large-cell lymphomas. |
| Q74813259 | BLM heterozygosity and the risk of colorectal cancer |
| Q60933652 | BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2 |
| Q36854437 | BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma |
| Q79407985 | BRCA mutation frequency and penetrance: new data, old debate |
| Q47637460 | BRCA mutations and risk of prostate cancer in Ashkenazi Jews |
| Q44064681 | BRCA mutations in women with ductal carcinoma in situ |
| Q43459769 | BRCA-associated breast cancer in young women |
| Q74530684 | BRCA-associated breast cancer: absence of a characteristic immunophenotype |
| Q84814806 | BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels |
| Q64039257 | BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry |
| Q44444100 | BRCA1 and BRCA2 germline mutations in lymphoma patients |
| Q52897865 | BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q33833602 | Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer |
| Q56928439 | Breast MRI for Women With Hereditary Cancer Risk |
| Q114182645 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q53265333 | Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q46520947 | Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. |
| Q84147822 | Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility |
| Q38466484 | Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. |
| Q92001832 | CHEK2 Alleles Predispose to Renal Cancer in Poland-In Reply |
| Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q91636751 | Cancer Susceptibility Mutations in Patients With Urothelial Malignancies |
| Q36535630 | Cancer genetic testing and assisted reproduction |
| Q38180646 | Cancer genomics and inherited risk |
| Q36359653 | Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations |
| Q57907575 | Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing |
| Q101237548 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q92551430 | Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening |
| Q57907562 | Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes |
| Q91341465 | Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes |
| Q35693892 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci |
| Q102074935 | Characterization and Clinical Outcomes of DNA Mismatch Repair Deficient (MMR-D) Small Bowel Adenocarcinoma |
| Q94476800 | Characterization of a germline splice site variant MLH1 c.678-3T>A in a Lynch syndrome family |
| Q42379886 | Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family |
| Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q37456280 | Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations |
| Q74696857 | Chromosomal and gene amplification in diffuse large B-cell lymphoma |
| Q92298237 | Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses |
| Q98905585 | Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses |
| Q39790653 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer |
| Q72384724 | Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23) |
| Q38175688 | Clinical features and management of BRCA1 and BRCA2-associated prostate cancer |
| Q36877519 | Clinical practice. Management of an inherited predisposition to breast cancer |
| Q90036958 | Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels |
| Q37544744 | Clonal cytogenetic abnormalities in Hodgkin's disease |
| Q103837522 | Clonal hematopoiesis is associated with risk of severe Covid-19 |
| Q72090516 | Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma |
| Q30992909 | Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes |
| Q81094552 | Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH |
| Q46440323 | Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
| Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q98512722 | Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial |
| Q36376718 | Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing |
| Q39398050 | Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing |
| Q56928444 | Considerations in genetic counseling for inherited breast cancer predisposition |
| Q93118070 | Correction to: Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer |
| Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
| Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q91090014 | Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
| Q92512625 | Correction: Toward automation of germline variant curation in clinical cancer genetics |
| Q57907570 | Counseling and Testing for Inherited Predisposition to Cancer |
| Q33911135 | Counselling framework for moderate-penetrance cancer-susceptibility mutations |
| Q92184158 | Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer |
| Q70127365 | Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations |
| Q67939153 | Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment |
| Q44469707 | Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q88674172 | DNA-Repair Gene Mutations in Metastatic Prostate Cancer |
| Q53229874 | Decade in review--genomics: a decade of discovery in cancer genomics. |
| Q92648539 | Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers |
| Q113241069 | Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management. |
| Q45136506 | Del (7)(q32) is associated with a subset of small lymphocytic lymphoma with plasmacytoid features |
| Q42804793 | Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma |
| Q37590819 | Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies |
| Q64979534 | Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. |
| Q56887893 | Development of Clinical Domain Working Groups for the Clinical Genome Resource (ClinGen): lessons learned and plans for the future |
| Q37797761 | Diagnosing hereditary colorectal cancer |
| Q40640025 | Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients |
| Q60472142 | Discovery of common and rare genetic risk variants for colorectal cancer |
| Q35846927 | Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women |
| Q81562470 | EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations |
| Q39297259 | Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group |
| Q51775978 | Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. |
| Q47614988 | Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers |
| Q91855769 | Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial |
| Q56928441 | Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations |
| Q47157633 | Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk |
| Q56928445 | Estrogen Receptor-Beta Expression in Hereditary Breast Cancer |
| Q44182747 | Estrogen receptor genotypes and haplotypes associated with breast cancer risk |
| Q36963476 | Ethical and legal aspects of cancer genetic testing |
| Q42253099 | Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? |
| Q37762189 | Ethicolegal aspects of cancer genetics |
| Q95469161 | Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder |
| Q36890898 | Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
| Q52560326 | Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. |
| Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
| Q37745041 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
| Q56928438 | Evaluation of germline PTEN mutations in endometrial cancer patients |
| Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
| Q35999309 | FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor |
| Q35582709 | Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations |
| Q50906340 | Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives. |
| Q92045716 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights |
| Q71834007 | Familial acute myeloid leukemia and DiGuglielmo syndrome |
| Q51924980 | Familial adenomatous polyposis and mental retardation caused by a de novo chromosomal deletion at 5q15-q22: report of a case. |
| Q54559294 | Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q68094638 | Follicular lymphoma with t(8;14)(q24;q32): a distinct clinical and molecular subset of t(8;14)-bearing lymphomas |
| Q57908288 | Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer |
| Q24798279 | Frequency of CHEK2*1100delC in New York breast cancer cases and controls |
| Q41193996 | Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families |
| Q92836607 | Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma |
| Q47298095 | Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36408445 | Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant |
| Q39402487 | Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology |
| Q33570452 | Genetic analysis of the early natural history of epithelial ovarian carcinoma |
| Q35208177 | Genetic architecture of prostate cancer in the Ashkenazi Jewish population |
| Q92588645 | Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes |
| Q95800172 | Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education |
| Q38021463 | Genetic testing in gastrointestinal cancers: a case-based approach. |
| Q63976721 | Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer |
| Q35240086 | Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q33882519 | Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma |
| Q44217660 | Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. |
| Q104754495 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology |
| Q36384036 | Genetic/familial high-risk assessment: breast and ovarian |
| Q84284656 | Genetic/familial high-risk assessment: breast and ovarian |
| Q85253905 | Genetic/familial high-risk assessment: breast and ovarian, version 1.2014 |
| Q89737463 | Genetically Determined Height and Risk of Non-hodgkin Lymphoma |
| Q28393571 | Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes |
| Q30513982 | Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine |
| Q37275252 | Genitourinary Cancers Other than Prostate Cancer in a BRCA-tested Cohort from a Single Institution |
| Q57907606 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant |
| Q98216310 | Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk |
| Q37581573 | Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk |
| Q37637724 | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q34193988 | Genome-wide association studies of cancer |
| Q37785242 | Genome-wide association studies of cancer predisposition |
| Q37776479 | Genome-wide association studies of cancer: principles and potential utility. |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q34288685 | Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region |
| Q28943339 | Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia |
| Q28248768 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q36670312 | Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. |
| Q37242239 | Genomic Biomarkers for Breast Cancer Risk |
| Q80893894 | Genomic profiles for disease risk: predictive or premature? |
| Q37677557 | Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer |
| Q37019841 | Germline BRCA mutations denote a clinicopathologic subset of prostate cancer |
| Q71107825 | Germline BRCA1 185delAG mutations in Jewish women with breast cancer |
| Q47122725 | Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care |
| Q33423823 | Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q56928422 | Germline PALB2 mutation analysis in breast-pancreas cancer families |
| Q112577396 | Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination |
| Q90697818 | Germline SDHA mutations in children and adults with cancer |
| Q33817011 | Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. |
| Q64083344 | Germline deletion of in familial acute lymphoblastic leukemia |
| Q24594891 | Germline mutations in BAP1 predispose to melanocytic tumors |
| Q52646188 | Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. |
| Q61970277 | Germline mutations ofAXIN2are not associated with nonsyndromic colorectal cancer |
| Q43879300 | Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host |
| Q54465029 | HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes. |
| Q34385784 | Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study |
| Q35881432 | Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study |
| Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
| Q90597648 | Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q36002146 | Hereditary cancer predisposition syndromes |
| Q35934068 | Hereditary ovarian cancer in Ashkenazi Jews |
| Q33289120 | Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis |
| Q34426654 | Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power |
| Q58865352 | High-depth whole genome sequencing of a large population-specific reference panel: Enhancing sensitivity, accuracy, and imputation |
| Q52715920 | High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. |
| Q34263742 | Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q91889338 | Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36754771 | Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q37540235 | Identification of germline genetic mutations in patients with pancreatic cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q100568879 | Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects |
| Q90460444 | Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test |
| Q68494070 | Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral T-cell lymphomas and lymphomas of uncertain lineage, including 12 Ki-1 positive lymphomas |
| Q84452748 | Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel |
| Q36763684 | Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer |
| Q42781699 | Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families |
| Q38375854 | Including additional controls from public databases improves the power of a genome-wide association study |
| Q37010546 | Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q56928443 | Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers |
| Q53345090 | Increased frequency of disease-causing MYH mutations in colon cancer families. |
| Q45003956 | Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers |
| Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
| Q37179254 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer |
| Q99634290 | Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk |
| Q57907552 | Inherited mutations in breast cancer patients with and without multiple primary cancers |
| Q37785233 | Inherited predisposition to cancer: introduction and overview |
| Q90631958 | Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways |
| Q54581835 | Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. |
| Q57455607 | Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes |
| Q48267403 | Integrative clinical genomics of metastatic cancer |
| Q38719280 | Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling |
| Q53527930 | Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. |
| Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
| Q77585710 | Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma |
| Q56928416 | Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis |
| Q68475812 | Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma |
| Q69366121 | Leukemic differentiation of a mediastinal germ cell tumor |
| Q57250691 | Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping |
| Q80945891 | Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mapping |
| Q34381064 | Low incidence of BRCA2 mutations in breast carcinoma and other cancers |
| Q46737936 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma |
| Q56565980 | MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner |
| Q57907609 | MP36-06 UTILITY OF PROSPECTIVE PATHOLOGIC EVALUATION TO INFORM CLINICAL GENETIC TESTING FOR HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA |
| Q57907613 | MP61-05 PILOT INVESTIGATION OF VARIANTS IN DNA REPAIR PATHWAYS AND ASSOCIATION WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN BLADDER CANCER |
| Q38349788 | MSH6 germline mutations are rare in colorectal cancer families. |
| Q80859201 | MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie |
| Q68292556 | MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q89685277 | Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk |
| Q56089167 | Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer |
| Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q36675182 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia |
| Q58096218 | Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer |
| Q57908377 | Modeling Genetic Risk of Breast Cancer |
| Q69742146 | Molecular analysis of breaks in BCL-1 proto-oncogene in B-cell lymphomas with abnormalities of 11q13 |
| Q69695648 | Molecular analysis of structural chromosome changes affecting chromosome band 11q23 |
| Q47704630 | Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers |
| Q51155217 | Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. |
| Q88088694 | Multigene Testing for Hereditary Cancer: When, Why, and How |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q56928410 | Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net? |
| Q50222046 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. |
| Q99585109 | Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers |
| Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
| Q37329596 | Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells |
| Q39045746 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. |
| Q91664337 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 |
| Q28252491 | Network modeling links breast cancer susceptibility and centrosome dysfunction |
| Q56928425 | New Pharmacogenomic Paradigm in Breast Cancer Treatment |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q24798887 | No major association between TGFBR1*6A and prostate cancer |
| Q56359054 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer |
| Q48124027 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. |
| Q112721375 | Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia |
| Q34162534 | Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q92133140 | Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2 |
| Q37200563 | Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes |
| Q52123195 | Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. |
| Q45140483 | Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q36158193 | Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up |
| Q57907619 | PD10-05 OUTCOME OF GENETIC EVALUATION OF KIDNEY CANCER PATIENTS REFERRED FOR SUSPECTED HEREDITARY CANCER SYNDROMES |
| Q99408595 | Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q90070074 | Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing |
| Q35082635 | Personalized medicine: new genomics, old lessons |
| Q89454638 | Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis |
| Q57907624 | Pilot investigation of variants in DNA repair pathways and association with response to platinum-based chemotherapy in bladder cancer |
| Q47192462 | Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
| Q35100152 | Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q36882484 | Prediction of germline mutations and cancer risk in the Lynch syndrome |
| Q56928426 | Preface |
| Q79428803 | Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine |
| Q37877648 | Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer |
| Q89440390 | Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma |
| Q37356530 | Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer |
| Q78178553 | Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer |
| Q36065462 | Prevention and management of hereditary breast cancer |
| Q87966864 | Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms |
| Q92551395 | Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling |
| Q88817029 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making |
| Q94562441 | Protein-altering germline mutations implicate novel genes related to lung cancer development |
| Q38763072 | Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer |
| Q39638347 | Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q51026427 | Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. |
| Q40677864 | Quantitating familial cancer risk: a resource for clinical oncologists |
| Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
| Q70863351 | REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma |
| Q41768169 | Rare de novo germline copy-number variation in testicular cancer |
| Q42672216 | Rare variants in XRCC2 as breast cancer susceptibility alleles |
| Q56928442 | Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers |
| Q72529454 | Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma |
| Q72327581 | Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma |
| Q41376599 | Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium |
| Q34064381 | Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium |
| Q34385912 | Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer |
| Q57908394 | Reducing the Risk of Gynecologic Cancer in the Lynch Syndrome |
| Q35444793 | Referral for cancer genetics consultation: a review and compilation of risk assessment criteria |
| Q36119158 | Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women |
| Q37130135 | Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels |
| Q53539899 | Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. |
| Q57908386 | Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study |
| Q39531185 | Revealing the incidentalome when targeting the tumor genome |
| Q56928449 | Risk of Endometrial Carcinoma Associated with BRCA Mutation |
| Q56928436 | Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families |
| Q44832461 | Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer |
| Q57908414 | Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation |
| Q34749278 | Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study |
| Q34129784 | Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation |
| Q56928415 | Risks to Relatives in Genomic Research: A Duty to Warn? |
| Q74784103 | Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk |
| Q34184913 | Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins |
| Q112721162 | Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes |
| Q46254589 | Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q44732177 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? |
| Q56915483 | Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma |
| Q42616545 | Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management |
| Q70116789 | Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia |
| Q35012736 | Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers |
| Q39816174 | Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. |
| Q41785590 | Susceptibility loci associated with prostate cancer progression and mortality |
| Q28943260 | Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies |
| Q83113260 | Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection |
| Q73881429 | TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies |
| Q44765711 | TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies |
| Q46838391 | Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update |
| Q102074939 | Targeting Germline and Tumor Associated Nucleotide Excision Repair Defects in Cancer |
| Q73229775 | TbetaR-I(6A) is a candidate tumor susceptibility allele |
| Q80597182 | The "duty to warn" a patient's family members about hereditary disease risks |
| Q34858803 | The 6q22.33 locus and breast cancer susceptibility |
| Q44930023 | The APCI1307K allele and breast cancer risk |
| Q74796496 | The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4 |
| Q33301585 | The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q57907556 | The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results |
| Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
| Q34113976 | The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop |
| Q40414571 | The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds |
| Q57250766 | The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% |
| Q41226231 | The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds |
| Q33784408 | The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk |
| Q34161196 | The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population |
| Q38789283 | The future of clinical cancer genomics |
| Q35855040 | The genetics of familial lymphomas |
| Q33946674 | The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations |
| Q46125784 | The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members |
| Q35247248 | The signatures of autozygosity among patients with colorectal cancer. |
| Q55047407 | Time to check CHEK2 in families with breast cancer? |
| Q35793648 | Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements |
| Q91763327 | Toward automation of germline variant curation in clinical cancer genetics |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q38162361 | Translating genomics in cancer care |
| Q91776847 | Tumour lineage shapes BRCA-mediated phenotypes |
| Q38727177 | Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status |
| Q33820594 | Two decades after BRCA: setting paradigms in personalized cancer care and prevention |
| Q57285472 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q47855086 | Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. |
| Q98293212 | Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer |
| Q24679634 | Unique de novo mutation of BRCA2 in a woman with early onset breast cancer |
| Q39639274 | Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations |
| Q39124690 | Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma |
| Q97534749 | Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial |
| Q36716606 | Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma |
| Q79203534 | Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer |
| Q81186123 | Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms |
| Q68059250 | Variant t(8;14) translocations in non-Burkitt's non-Hodgkin's lymphomas |
| Q24632704 | Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma |
| Q37636770 | Variants at IRX4 as prostate cancer expression quantitative trait loci |
| Q34841443 | Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk |
| Q34775338 | Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk |
| Q36028638 | Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry |
| Q52590782 | cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. |
| Q70482961 | p53 mutations are associated with histologic transformation of follicular lymphoma |
| Q71789494 | p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32) |
| Q69775407 | t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma |
| Q35343931 | t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation |
| Egyptian Arabic (arz / Q29919) | كينيث اوفيت | wikipedia |
| Kenneth Offit | wikipedia | |
| nb | Kenneth Offit | wikipedia |
Search more.